Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR.

ABSTRACT:

Background

Several retrospective studies have demonstrated an association between genome-wide DNA methylation status (GWMS) and clinical outcomes after treatment with anti-epidermal growth factor receptor antibody in metastatic colorectal cancer (mCRC). This biomarker study evaluated the association of GWMS with clinical outcomes in mCRC patients who were enrolled in a randomized phase II DEEPER trial of comparing modified (m)-FOLFOXIRI plus bevacizumab (Bev) and m-FOLFOXIRI plus cetuximab (Cet) as first-line treatment.

Patients and methods

GWMS was measured using tumor tissues which were collected from patients with tissue samples available in the DEEPER trial. In addition, tumor tissues were classified into high-methylated colorectal cancer (HMCC) and low-methylated colore

SUBMITTER: Ouchi K 

PROVIDER: S-EPMC12167864 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature